Motion Sickness Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects With Open-Label Follow-Up
Verified date | May 2023 |
Source | Repurposed Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With Open-Label Follow-Up
Status | Completed |
Enrollment | 98 |
Est. completion date | November 23, 2020 |
Est. primary completion date | November 23, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: 1. Provision of a signed and dated Informed Consent Form (ICF). 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 55 and over. 4. In good general health as evidenced by medical history with no recent history or current diagnosis of uncontrolled clinical problems as assessed by the Principal Investigator (PI) or qualified designee. 5. Ability to take intranasal medication and willingness to adhere to the study schedule and time constraints. 6. Agreement to adhere to the following lifestyle compliance considerations: - Refrain from consumption of grapefruit and any substance containing grapefruit for seven days prior to, during, and for seven days after the three Treatment Days. - Abstain from alcohol for 24 hours prior to first dose of study medication and during the three Treatment Days. Exclusion Criteria: 1. Known allergic reactions to scopolamine or other anticholinergics. 2. Currently prescribed any of the following medication types and used within the specified washout periods below: - any form of scopolamine (including Transderm ScopĀ®) (washout 5 days) - belladonna alkaloids (washout 2 weeks), - antihistamines (including meclizine) (washout 2 weeks), - tricyclic antidepressants (washout 2 weeks), - muscle relaxants (washout 4 days) and - nasal decongestants (washout 4 days) 3. Hospitalization or significant surgery requiring hospital admittance within the past six months. 4. Treatment with another investigational drug or other intervention within the past 30 days. 5. Having donated blood or plasma or suffered significant blood loss within the past 30 days. 6. Having any of the following medical conditions within the last two years or if any of the following medical conditions were experienced more than two years ago and are deemed clinically significant by the PI or qualified designee: - Significant gastrointestinal disorder, asthma, or seizure disorders. - History of cardiovascular disease. - History of vestibular disorders. - History of narrow-angle glaucoma. - History of urinary retention problems. - History of alcohol or drug abuse. - Nasal, nasal sinus, or nasal mucosa surgery. |
Country | Name | City | State |
---|---|---|---|
United States | Collaborative Neuroscience Network, LLC | Long Beach | California |
Lead Sponsor | Collaborator |
---|---|
Repurposed Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The efficacy endpoint is incidence of subjects who developed motion sickness and requested further treatment (i.e., subjects who received rescue medication). | The efficacy endpoint is incidence of subjects who developed motion sickness and requested further treatment (i.e., subjects who received rescue medication) during an 8 hour voyage on Treatment Day 1. | During voyage on Treatment Day 1. | |
Primary | Safety of DPI-386 Nasal Gel compared to placebo nasal gel with an emphasis on cognitive adverse events. | Safety endpoint is the incidence of adverse events. | During all four Treatment Days | |
Secondary | Severity of nausea as measured by the Visual Analog Scale (VAS) over the treatment period. | Respondents specify their degree of nausea by indicating a point along a continuous 100 mm line between two end-points; left one is for "No nausea" and the right one for "Very severe nausea". Scoring is based on the length from left point and a higher score means more severe degree of nausea (Spinks & Wasiak, 2011). | During Treatment Day 1 voyage. | |
Secondary | Safety in terms of cognition as measured by the Psychomotor Vigilance Task (PVT). | The PVT is a neurocognitive assessment that measures alertness and tests sustained attention and reaction time. It was originally developed for sleep studies, and involves simple reaction time testing by requiring the participant to push a button as soon as the stimulus (a light) appears. After a response, the reaction time (in ms) is displayed. The inter-stimulus interval varies from two to 10 seconds, so it is not predictable, and the entire task takes 10 minutes (Dorrian, Rogers, & Dinges, 2005). There are also shorter versions which have been validated as reasonable substitutes for the 10 minute version, such as the five minute (Lamond, Dawson, & Roach, 2005)) and three minute versions (Grant, et al., (2017). | During Treatment Day 1 voyage | |
Secondary | Describe the pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel. | PK parameters to be measured by Maximum Observed Plasma Concentration (Cmax) | At time points -60, 30, 90, 120, 180, 330, 390, 450, 480 and 600 minutes during Treatment Days 2-4. | |
Secondary | Describe the pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel. | PK parameters to be measured by Time to Reach Maximum Observed Plasma Concentration (Tmax). | At time points -60, 30, 90, 120, 180, 330, 390, 450, 480 and 600 minutes during Treatment Days 2-4. | |
Secondary | Describe the pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel. | PK parameters to be measured by Area Under the Curve (AUC) | At time points -60, 30, 90, 120, 180, 330, 390, 450, 480 and 600 minutes during Treatment Days 2-4. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Recruiting |
NCT06128707 -
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
|
||
Completed |
NCT05611814 -
Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms
|
N/A | |
Recruiting |
NCT06106256 -
Three-Axis Wearable Adaptive Vestibular Stimulator
|
N/A | |
Completed |
NCT02839135 -
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
|
Phase 1 | |
Completed |
NCT04420949 -
Sensory Training for Visual Motion Sickness
|
N/A | |
Completed |
NCT04184115 -
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
|
Phase 3 | |
Terminated |
NCT04219982 -
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
|
Phase 2/Phase 3 | |
Terminated |
NCT02155309 -
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
|
Phase 2/Phase 3 | |
Completed |
NCT04947423 -
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
|
Phase 3 | |
Recruiting |
NCT05903924 -
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
|
Phase 3 | |
Recruiting |
NCT04999449 -
Nebulizer Delivery of Intranasal Scopolamine
|
Phase 1 | |
Recruiting |
NCT05886660 -
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
|
Phase 2 | |
Completed |
NCT03755596 -
Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness
|
Phase 4 | |
Recruiting |
NCT05628220 -
Motion Sickness Desensitization Using VR
|
N/A | |
Recruiting |
NCT06138613 -
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
|
Phase 3 | |
Completed |
NCT04327661 -
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
|
Phase 3 | |
Completed |
NCT06232785 -
Gynecologic Endoscopic Surgery of Female Motion Sickness Patients
|
Phase 4 | |
Completed |
NCT06056622 -
Motion Sickness Rehabilitation for Virtual Reality
|
N/A | |
Withdrawn |
NCT04331561 -
Sensory Training for Orientation and Balance
|
N/A |